Webdisclosure.com

Search

INVENTIVA (EPA:IVA) Inventiva announces the screening of the first patient in LEGEND, a Phase IIa combination trial with lanifibranor and empagliflozin in patients with NASH and T2D

Directive transparence : information réglementée

07/07/2022 22:00